

1 **Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic**  
2 **fibrosis**

3 Ryan Marsh <sup>a</sup>, Claudio Dos Santos <sup>b</sup>, Alexander Yule <sup>c,d</sup>, Neele S Dellschaft <sup>e</sup>, Caroline L Hoad <sup>e</sup>,  
4 Christabella Ng <sup>c,d</sup>, Giles Major <sup>c,f</sup>, Alan R Smyth <sup>c,d,g</sup>, Damian Rivett <sup>b,\*</sup>, Christopher van der Gast <sup>a,h,\*</sup>

5  
6 <sup>a</sup> Department of Applied Sciences, Northumbria University, Newcastle, UK

7 <sup>b</sup> Department of Natural Sciences, Manchester Metropolitan University, UK

8 <sup>c</sup> School of Medicine, University of Nottingham, UK

9 <sup>d</sup> NIHR Nottingham Biomedical Research Centre, UK

10 <sup>e</sup> Sir Peter Mansfield Imaging Centre, University of Nottingham, UK

11 <sup>f</sup> Nestlé Institute of Health Sciences, Société des Produits Nestlé, Lausanne, Switzerland

12 <sup>g</sup> School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK

13 <sup>h</sup> Department of Respiratory Medicine, Northern Care Alliance NHS Foundation Trust, Salford, UK

14

15 \* Correspondence to: Professor Chris van der Gast, Department of Applied Sciences, Ellison Building,  
16 Newcastle upon Tyne, NE1 8ST, UK; [chris.vandergast@northumbria.ac.uk](mailto:chris.vandergast@northumbria.ac.uk)

17 Dr Damian Rivett, Department of Natural Sciences, John Dalton Building, Chester Street, Manchester,  
18 M1 5GD, UK; [D.Rivett@mmu.ac.uk](mailto:D.Rivett@mmu.ac.uk)

19

20 Keywords: gut microbiome, dysbiosis, pulmonary antibiotics, CFTR modulator therapy, Kaftrio, Trikafta

21 **Abstract**

22 *Background:* There is a paucity of knowledge on the longer-term effects of CF transmembrane  
23 conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes.  
24 In a pilot study, we investigated longitudinal Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy on the gut  
25 microbiota, metabolomic functioning, and clinical outcomes in people with CF (pwCF).

26  
27 *Study design:* Faecal samples from 20 pwCF were acquired before and then following 3, 6, and 17+  
28 months of ETI therapy. Samples were subjected to microbiota sequencing and targeted metabolomics  
29 to profile and quantify short-chain fatty acid composition. Ten healthy matched controls were included  
30 for comparison. Clinical data, including markers of intestinal function were integrated to investigate  
31 relationships.

32  
33 *Results:* Extended ETI therapy increased core microbiota diversity and composition, which translated  
34 to gradual shifts in whole microbiota composition towards that observed in healthy controls. Despite  
35 becoming more similar over time, CF microbiota and functional metabolite compositions remained  
36 significantly different to healthy controls. Antibiotic treatment for pulmonary infection significantly  
37 explained a relatively large degree of variation within the whole microbiota and rarer satellite taxa.  
38 Clinical outcomes were not significantly different following ETI.

39  
40 *Conclusions:* A positive trajectory towards the microbiota observed in healthy controls was found.  
41 However, we posit that progression was predominately impeded by pulmonary antibiotics  
42 administration. We recommend future studies use integrated omics approaches within a combination  
43 of long-term longitudinal patient studies and model experimental systems. This will deepen our  
44 understanding of the impacts of CFTR modulator therapy and respiratory antibiotic interventions upon  
45 the gut microbiome and gastrointestinal pathophysiology in CF.

## 46 1. Introduction

47 Alongside the classical respiratory complications of cystic fibrosis (CF) are also the gastrointestinal  
48 abnormalities of disease. People with CF (pwCF) suffer from persistent intestinal symptoms and  
49 abnormalities that impact both morbidity and mortality [1]. This has continued despite the transition of  
50 treatment for CF entering the phase of highly effective CFTR modulator therapies, which correct the  
51 underlying defect of chloride and bicarbonate transport across epithelial surfaces of the body [2].  
52 Although the majority of pwCF are now receiving CFTR modulator based therapy [3], the need to better  
53 understand the relationships between intestinal symptoms and abnormalities persists, as determined  
54 by pwCF, carers, and clinicians [4,5]. It is understood that intestinal dysbiosis, that is the disruption of  
55 the microbial communities inhabiting the intestinal tract, is frequent in CF and leads to compositions of  
56 bacteria distinctly different from healthy controls from birth and throughout adulthood [6–8]. Whilst this  
57 could be further compounded by the CF-associated lifestyle, such as dietary habits and frequent  
58 antibiotic usage [9,10], disruption of CFTR activity alone is seemingly sufficient to elicit structural  
59 changes to the microbiota [11]. Furthermore, the altered gut microbiota in pwCF has previously been  
60 associated with various manifestations of the GI tract [12–14]. Given this evidence, it is possible that  
61 CFTR modulators may alter the gut microbiota composition to resemble that of healthy individuals more  
62 closely, alongside improving other common intestinal abnormalities and symptoms in pwCF.

63 Previous studies investigating CFTR modulators and microbiota within the gastrointestinal tract have  
64 been mostly limited to Ivacaftor [15–18] and a couple of dual-modulator studies [17], including our  
65 previous work investigating the impact of Tezacaftor/Ivacaftor [19]. With respect to the microbiota  
66 structure, previous findings vary across studies incorporating different modulators, patient  
67 demographics, and treatment lengths [15–18]. Results for the frequently observed inflammation in the  
68 gut following modulator treatment are also contrasting. Some studies observed a reduction in faecal  
69 calprotectin following modulator usage [15,20,21], whilst others [16] and our own group [19], did not  
70 measure any notable reduction.

71 Following the approval of Elexacaftor/Tezacaftor/Ivacaftor (ETI) triple modulator therapy for pwCF from  
72 NHS England, over 60% of all pwCF in the United Kingdom are now registered users [3]. ETI therapy  
73 demonstrates increased clinical efficacy as compared to previous dual or mono-therapy approaches  
74 [22], yet little information is available on intestinal outcomes and the impact upon the gut microbiota.

75 Given the scarcity of current evidence, the aim of this pilot study was to therefore assess the impact of  
76 ETI therapy in pwCF upon the intestinal microbiota. We characterised the respective gut microbiota of  
77 pancreatic insufficient pwCF  $\geq 12$  years, with at least one copy of the F508del mutation, before and  
78 during ETI therapy of up to 23 months duration. Furthermore, we combined microbiota data with  
79 targeted metabolomics of quantified faecal short-chain fatty acids (SCFAs), patient clinical data, and  
80 markers of intestinal function as measured by magnetic resonance imaging (MRI) [23]. Patient  
81 symptoms were also measured before and after initiating ETI therapy. Samples and clinical data from  
82 10 matched healthy controls were available for analysis. We hypothesised that ETI therapy would  
83 increase gut microbiota diversity, reshape community structure, and potentially lead to functional  
84 changes to resemble outcomes measured in healthy controls.

85

## 86 **2. Methods**

### 87 *2.1. Study participants and design*

88 Twenty-four pwCF were initially recruited from Nottingham University Hospitals NHS Trust, with 20  
89 participants ultimately providing at least one faecal sample following ETI therapy to form the cohort for  
90 our observational study. Participants attended clinic at baseline, 3, and 6 months following the initiation  
91 of ETI. A subset of pwCF ( $n = 7$ ) also provided samples following extended ETI therapy of  $19.8 \pm 2.0$   
92 months (mean  $\pm$  SD), with a minimum time of 17 months additional treatment. Additional faecal samples  
93 and metadata for 10 age and sex-matched healthy controls from our previous study were available for  
94 microbiota and metabolomic comparison also [24]. During study visits, participants provided faecal  
95 samples and completed magnetic resonance imaging (MRI) scans following the consumption of a  
96 standardised meal plan to detail their gut function as conducted previously [24], alongside specifying  
97 gut symptoms. This included the validated PAC-SYM questionnaire [25]. The full study design, including  
98 protocols, methods, and other results are described in the Supplementary Methods & Results. An  
99 overview of participant clinical characteristics is detailed in Table 1, with comprehensive participant  
100 information and MRI data detailed in Tables S1 and S2, respectively. Access to the MRI data  
101 (unpublished) was kindly granted by the University of Nottingham MRI research team at the Sir Peter  
102 Mansfield Imaging Centre. Written informed consent, or parental consent and assent for paediatric  
103 participants, was obtained from all participants. Study approval was obtained from the UK National

104 Research Ethics Committee (20/PR/0508). All faecal samples obtained were immediately stored at -  
105 80°C prior to processing for microbiota sequencing and metabolomics to reduce changes before  
106 downstream community analysis [26].

107

## 108 *2.2. Targeted amplicon sequencing*

109 DNA from dead or damaged cells, as well as extracellular DNA was excluded from analysis via cross-  
110 linking with propidium monoazide (PMA) prior to DNA extraction, as previously described [27]. Cellular  
111 pellets resuspended in PBS were loaded into the ZYMO Quick-DNA Fecal/Soil Microbe Miniprep Kit  
112 (Cambridge Bioscience, Cambridge, UK) as per the manufacturer's instructions. Dual mechanical-  
113 chemical sample disruption was performed using the FastPrep-24 5G instrument (MP Biomedicals,  
114 California, USA). Following DNA extraction, approximately 20 ng of template DNA was then amplified  
115 using Q5 high-fidelity DNA polymerase (New England Biolabs, Hitchin, UK) using a paired-end  
116 sequencing approach targeting the bacterial 16S rRNA gene region (V4-V5) as previously described  
117 [24]. Pooled barcoded amplicon libraries were sequenced on the Illumina MiSeq platform (V3  
118 Chemistry). Extended methodology, primers and PCR conditions can be found in the Supplementary  
119 Methods & Results.

120

## 121 *2.3. Sequence processing and analysis*

122 Sequence processing and data analysis were then carried out in R (Version 4.2.1), utilising the  
123 packages DADA2 [28] and decontam [29]. The full protocol is detailed in the Supplementary Methods  
124 & Results. Raw sequence data reported in this study has been deposited in the European Nucleotide  
125 Archive under the study accession number PRJEB61286.

126

## 127 *2.4 Gas-chromatography mass-spectrometry (GC-MS) of faecal samples to investigate SCFA levels.*

128 GC-MS analysis was carried out using an Agilent 7890B/5977 Single Quadrupole Mass Selective  
129 Detector (MSD) (Agilent Technologies) equipped with a non-polar HP-5ms Ultra Inert capillary column  
130 (30 m × 0.25 mm × 0.25 µm) (Agilent Technologies). Faecal sample processing to obtain, and then to  
131 derivatise SCFAs prior to GC-MS analysis, was carried out as previously described [19]. Following  
132 derivatisation, samples were loaded onto the GC-MS and injected using an Agilent 7693 Autosampler.  
133 MS grade water processed in parallel was used as a blank sample to correct the background. Selected

134 ion monitoring (SIM) mode was used for subsequent analyses; all confirmation and target ions lists are  
135 summarised in Table S3. Agilent MassHunter workstation version B.07.00 programs were used to  
136 perform post-run analyses. A <sup>13</sup>C-short chain fatty acids stool mixture (Merck Life Science, Poole, UK)  
137 was used as the internal standard to normalise all spectra obtained prior to analyses. A volatile fatty  
138 acid mixture (Merck Life Science, UK) was used to construct calibration curves for the quantification of  
139 target metabolites. Extended information surrounding sample processing, SCFA extraction,  
140 derivatisation, and GC-MS parameters can be found in the Supplementary Methods & Results.

141

#### 142 *2.5. Faecal Calprotectin measurement*

143 Stool was extracted for downstream assays using the ScheBo® Master Quick-Prep (ScheBo Biotech,  
144 Giessen, Germany), according to the manufacturer instructions. Faecal calprotectin was analysed using  
145 the BÜHLMANN fCAL ELISA (Bühlmann Laboratories Aktiengesellschaft, Schönenbuch, Switzerland),  
146 according to the manufacturer's protocol.

147

#### 148 *2.6. Statistical Analysis*

149 Regression analysis, including calculated coefficients of determination ( $r^2$ ), degrees of freedom (df),  $F$ -  
150 statistic and significance values ( $P$ ) were utilised for microbial partitioning into common core and rarer  
151 satellite groups, and were calculated using XLSTAT v2021.1.1 (Addinsoft, Paris, France). Fisher's  
152 alpha index of diversity and the Bray-Curtis index of similarity were calculated using PAST v3.21 [30].  
153 Tests for significant differences in microbiota diversity and SCFAs were performed using Kruskal-Wallis  
154 in XLSTAT. Student's t-tests used to determine differences in metadata were also performed in  
155 XLSTAT. Analysis of similarities (ANOSIM) with Bonferroni correction was used to test for significance  
156 in microbiota and SCFA composition and was performed in PAST. Similarity of percentages (SIMPER)  
157 analysis, to determine which constituents drove compositional differences between groups, and was  
158 performed in PAST. Redundancy analysis (RDA), was performed in CANOCO v5 [31]. Statistical  
159 significance for all tests was deemed at the  $P \leq 0.05$  level.

160

**Table 1.** Overall clinical characteristics of controls and pwCF at baseline.

Characteristic	pwCF	Controls
Baseline Age (Mean $\pm$ SD)	21.0 $\pm$ 8.6	21.4 $\pm$ 7.4
Male (%)	15 (75)	5 (50)
Baseline BMI (Mean $\pm$ SD)	21.1 $\pm$ 3.4	22.9 $\pm$ 4.4
F508del/F508del (%)	13 (65)	0 (0)
Baseline FEV1% (Mean $\pm$ SD)	79.1 $\pm$ 20.5	-
Pancreatic insufficient (%)	20 (100)	0 (0)
Cystic fibrosis-related diabetes (%)	4 (20)	-
Antibiotics during study (%)	14 (70)	0 (0)


161

162

### 163 3. Results

164 Following sequence processing and taxa assignment, the microbiota data across each pwCF treatment  
165 period from baseline, and the healthy control participants was partitioned for further sub-analysis.  
166 Microbiota data were partitioned into common abundant core taxa, and rarer less frequent satellite taxa  
167 following the establishment of significant distribution abundance relationships of the taxa across all  
168 treatment duration groups and the healthy control participants (Figure S1). The core taxa (Table S4)  
169 constituted 70.1 % of the total abundance for the healthy controls, whilst across pwCF they averaged  
170 30.0%  $\pm$  6.1 (Mean  $\pm$  SD).

171 Diversity of the whole microbiota, core taxa, and satellite taxa was plotted across the increasing ETI  
172 treatment periods in pwCF (Figure 1A). Overall, the diversity changes across all microbiota partitions  
173 included a gradual decline until 6 months of ETI treatment, highlighted by the significant reduction in  
174 diversity between baseline and 6 months for the whole microbiota ( $P = 0.001$ ), core taxa ( $P = 0.003$ ),  
175 and satellite taxa ( $P = 0.001$ ) (Table S5). This was then succeeded by an increase in diversity following  
176 extended ETI treatment. The most pronounced change was the core taxa, for which diversity greatly  
177 increased following extended ETI treatment relative to other time points, reflected by significant  
178 increases in diversity compared to both baseline ( $P = 0.001$ ) and the 6-month time period ( $P < 0.001$ )  
179 (Table S5). Despite the positive trajectory of diversity in pwCF following extended ETI therapy, there  
180 remained distinct differences when compared to healthy controls (Figure 1B, Table S6), whereby all  
181 partitions of the microbiota were significantly more diverse as compared to pwCF ( $P = 0.001$ ).



182

183 **Figure 1.** Microbiota diversity compared across groups utilising Fisher's alpha index of diversity. Black plots  
 184 indicate the whole microbiota, whilst orange and grey denote the core and satellite taxa respectively. (A) Diversity  
 185 across pwCF at baseline or following ETI treatment. Black circles denote individual patient participant data. Error  
 186 bars represent 1.5 times the inter-quartile range (IQR). Blue line indicates trend and direction of travel through the  
 187 median of each treatment time point. Asterisks denote significant differences in diversity between treatment periods  
 188 (sequential and to baseline) following Kruskal-Wallis testing (Table S5). (B) Diversity of pwCF and also healthy  
 189 controls for comparison. Black circles denote individual patient participant data. Error bars represent 1.5 times the  
 190 inter-quartile range (IQR). Asterisks denote significant differences in diversity between pwCF treatment periods  
 191 and healthy controls following Kruskal-Wallis testing (Table S6). Abbreviations; 0,3 & 6 – Sampling time point  
 192 (months), 17+ – Extended (17+ months) sampling period, HC – Healthy control participants. *P* values; \*\*\*, *P* ≤  
 193 0.0001, \*\*, *P* ≤ 0.001, \*, *P* ≤ 0.05.


194

195 When analysing microbiota composition throughout ETI treatment, similarity of the whole microbiota  
 196 composition increased in pwCF as ETI treatment progressed, with a mean similarity ( $\pm$  SD) of  $0.32 \pm$   
 197  $0.09$  following extended ETI (Figure 2A). Within-group similarity did however remain larger in the healthy  
 198 controls, with a mean similarity of  $0.44 \pm 0.06$ . Within-group similarity for the satellite taxa initially  
 199 increased but was relatively consistent throughout ETI treatment and was comparable to healthy  
 200 controls following extended ETI ( $0.19 \pm 0.04$  and  $0.19 \pm 0.07$ , respectively). The core taxa similarity,  
 201 however, increased in pwCF following extended ETI, surpassing that of healthy control participants  
 202 ( $0.60 \pm 0.12$  and  $0.57 \pm 0.06$ , respectively). When comparing the composition of the microbiota between  
 203 sequential ETI treatment periods (Figure 2B), the largest similarity across the whole microbiota and  
 204 core taxa could be observed between 6 months and the extended ETI period, whilst the satellite taxa  
 205 had no clear direction of travel. There were, however, significant differences between both the core (*P*



206 < 0.001) and satellite ( $P = 0.035$ ) taxa between months 3 and 6 of ETI treatment (Table S7). When  
 207 comparisons were extended to include healthy controls (Figure 2C), all partitions of the microbiota in  
 208 pwCF illustrated the highest resemblance to healthy controls following the extended ETI treatment  
 209 period. Regardless of this increased similarity, microbiota composition of the healthy controls remained  
 210 highly distinct and significantly different ( $P < 0.001$ ) from pwCF throughout the study period (Figure 2C,  
 211 Table S8).

212



213

214 **Figure 2.** Microbiota similarity compared across groups utilising the Bray-Curtis index of similarity. (A) Within group  
 215 similarity across pwCF at baseline or following ETI treatment, and healthy controls. (B) Between group similarity  
 216 change over time in pwCF. (C) Similarity between pwCF on ETI at various time points and healthy control  
 217 participants. Error bars represent standard deviation of the mean. Asterisks indicate significant differences in  
 218 microbiota composition following the use of one-way ANOSIM testing. Summary statistics are presented in Tables  
 219 S7-8.  $P$  values; \*\*\*,  $P \leq 0.0001$ , \*\*,  $P \leq 0.001$ , \*,  $P \leq 0.05$ .

220

221 To understand which taxa were driving the dissimilarity maintained between healthy control participants  
 222 and pwCF following extended ETI therapy, SIMPER analysis was conducted (Table 2). The top drivers  
 223 of dissimilarity between the groups were *Blautia* sp. (OTU 1), *Bifidobacterium adolescentis*, *Bacteroides*  
 224 *dorei*, *Eubacterium rectale*, and *Anaerostipes hadrus*. Overall, 24 taxa comprised over 50% of the  
 225 dissimilarity between the groups and this consisted of many prominent SCFA producing bacteria from  
 226 other genera, including *Faecalibacterium*, *Ruminococcus*, and *Collinsella*. Interestingly, some of these  
 227 taxa were increased in the pwCF group compared to the healthy controls. Additional SIMPER analysis

228 between baseline and following extended ETI therapy revealed that similar taxa were also drivers of  
229 the change seen across the ETI treatment period in pwCF (Table S9).

230 To investigate the relationships between participant clinical variables and microbiota composition,  
231 redundancy analysis (RDA) was performed. Within comparisons between pwCF following extended ETI  
232 and the healthy control participants (Table 3), whole microbiota variability was explained by (in  
233 ascending order) the presence of CF disease, antibiotic usage, and age. For the core taxa analysis, CF  
234 disease was the primary driver of variation, with sex also contributing. CF disease was also the main  
235 contributor of variation in the satellite taxa, followed by antibiotic usage and patient small bowel water  
236 content (SBWC). When relating variability of the microbiota solely within pwCF (from baseline to  
237 extended ETI) (Table S10), multiple variables significantly explained the variation in the whole  
238 microbiota, including disease severity (FEV1%), BMI, antibiotic usage, sex, and SBWC. Excluding BMI,  
239 these variables also significantly explained variation across the core taxa. For the satellite taxa analysis,  
240 Age and ETI treatment length also significantly explained some of the variation. Species RDA biplots  
241 were then plotted to visualise how the taxa driving differences across pwCF and controls related to  
242 significant clinical variables identified from the RDA approach. Between the healthy controls and pwCF  
243 on extended ETI (Figure 3), a group of taxa containing *Faecalibacterium* and *Bacteroides* members  
244 collectively clustered strongly away from CF disease and the usage of antibiotics, whilst taxa such as  
245 *Blautia* sp. (OTU 1), *Ruminococcus gnavus*, *Enterococcus* sp. (OTU 26), and *Eubacterium hallii*  
246 demonstrated the opposite trend. Some taxa were explained primarily by both participant age and sex.  
247 This included *Blautia luti*, *Dorea longicatena*, *Holdemanella biformis*, *Bacteroides dorei*, *Escherichia*  
248 *coli*, and *Bifidobacterium adolescentis*. In terms of SBWC, this explained the variation across a group  
249 of taxa including *Fusicatenibacter saccharivorans* and *Gemmiger formicilis*. Within pwCF exclusively  
250 (baseline to extended ETI), different taxa and variables comprised the RDA biplot due to outcomes from  
251 the previous SIMPER and RDA analyses (Figure S2). Some similar trends were observed however,  
252 including the strong association of *Enterococcus* sp. (OTU 24) with antibiotic usage and *Blautia* sp.  
253 (OTU 1) away from more mild CF disease.

254

**Table 2.** Similarity of percentage (SIMPER) analysis of microbiota dissimilarity (Bray-Curtis) between healthy control and pwCF samples following 17+ months (extended) treatment with ETI.

Taxa	% Relative abundance		Av. Dissimilarity	% Contribution	Cumulative (%)
	17+ Months	Healthy Controls			
<i>Blautia 1</i>	11.70	4.91	3.24	4.53	4.53
<i>Bifidobacterium adolescentis</i>	4.90	0.81	2.35	3.28	7.81
<i>Bacteroides dorei</i>	3.79	3.35	2.12	2.95	10.77
<i>Eubacterium rectale</i>	3.68	4.78	2.02	2.82	13.58
<i>Anaerostipes hadrus</i>	4.35	1.99	2.00	2.79	16.37
<i>Fusicatenibacter saccharivorans</i>	5.73	3.69	1.96	2.74	19.11
<i>Ruminococcus bromii</i>	3.34	2.93	1.93	2.70	21.81
<i>Gemmiger formicilis</i>	4.24	1.05	1.90	2.65	24.46
<i>Blautia luti</i>	5.55	3.01	1.63	2.27	26.73
<i>Bacteroides vulgatus</i>	1.66	3.32	1.62	2.26	28.99
<i>Collinsella aerofaciens</i>	3.33	0.19	1.59	2.23	31.21
<i>Dorea longicatena</i>	4.39	1.79	1.47	2.05	33.26
<i>Eubacterium hallii</i>	4.81	2.39	1.26	1.76	35.02
<i>Escherichia coli</i>	2.27	1.99	1.26	1.76	36.78
<i>Blautia obeum</i>	0.98	2.51	1.15	1.61	38.38
<i>Ruminococcus gnavus</i>	2.48	0.04	1.13	1.58	39.96
<i>Bacteroides uniformis</i>	0.14	2.55	1.11	1.55	41.51
<i>Holdemanella bififormis</i>	2.01	0.45	1.09	1.52	43.03
<i>Blautia faecis</i>	2.12	2.30	0.98	1.38	44.40
<i>Faecalibacterium duncaniae</i>	2.09	2.15	0.98	1.37	45.78
<i>Enterococcus 26</i>	2.07	0.31	0.98	1.37	47.15
<i>Faecalibacterium longum</i>	0.42	2.19	0.96	1.35	48.49
<i>Ruminococcus faecis</i>	2.27	1.61	0.96	1.34	49.84
<i>Faecalibacterium prausnitzii</i>	0.00	2.04	0.95	1.32	51.16

255 Taxa identified as core are highlighted in orange, with satellite taxa highlighted in grey. The mean relative  
 256 abundance (%) across both groups is given, alongside the percentage contribution which is the mean dissimilarity  
 257 of taxa divided by the mean dissimilarity (71.26%) across samples. Cumulative percent does not equal 100% as  
 258 the list is not exhaustive, rather the taxa that make up 50% of dissimilarity between groups. Given the length of the  
 259 16S gene regions sequenced, taxon identification should be considered putative.

**Table 3.** Redundancy analysis to explain percent variation across whole microbiota, core, and satellite taxa of the significant clinical variables across healthy control participants and pwCF receiving 17+ months (extended) ETI therapy.


	Microbiota			Core taxa			Satellite taxa		
	Var. Exp (%)	pseudo- <i>F</i>	<i>P</i> (adj)	Var. Exp (%)	pseudo- <i>F</i>	<i>P</i> (adj)	Var. Exp (%)	pseudo- <i>F</i>	<i>P</i> (adj)
Age	10.1	2.0	0.008						
Antibiotics	10.6	2.0	0.018				10.8	1.9	0.012
CF Disease	13.3	2.3	0.002	27.5	5.7	0.002	16.0	3.3	0.002
SBWC							10.8	1.8	0.050
Sex				10.0	2.2	0.028			
<b>Total</b>	<b>23.9</b>			<b>37.5</b>			<b>37.6</b>		

261

262 Both the composition and absolute quantification of SCFAs from pwCF and healthy control samples  
 263 were also investigated (Figure S3). Combined, the relative abundance of acetic, propionic, and butyric  
 264 acid accounted for the vast majority of SCFAs across both the pwCF ETI treatment periods (94.0% ±  
 265 4.5, Mean ± SD) and healthy controls (89.6% ± 4.8, Mean ± SD). There were no significant differences  
 266 from baseline, or subsequent sampling periods, in the absolute concentration or relative abundance of  
 267 SCFAs across pwCF receiving ETI therapy (Figure S3, Tables S11-12). There were, however,  
 268 significant differences between ETI samples and healthy controls (Figure S3, Table S13-14). This  
 269 included significant increases in both absolute concentration and relative abundance of valeric (Figure  
 270 S3 A&C) and heptanoic acid (Figure S3 B&D) within healthy control samples compared with all ETI  
 271 sampling periods ( $P < 0.05$  in all instances), with hexanoic acid also significantly increased compared  
 272 to pwCF, except those on extended ETI ( $P = 0.143$ ) (Figure S3 B&D). On the contrary, the only  
 273 significantly increased SCFA in pwCF was butyric acid, with significantly higher concentrations  
 274 measured during the extended ETI sampling period as compared to health controls ( $P = 0.015$ ) (Figure  
 275 S3A).

276 The overall composition of SCFAs remained similar in pwCF throughout ETI therapy but remained  
 277 significantly different from healthy controls during both the 6 months and extended ETI therapy periods  
 278 ( $P < 0.05$  in all instances) (Table S15). Over 50% of this dissimilarity was driven by acetic and butyric  
 279 acid in both cases (Table S16). Exploratory RDA revealed that only a few SCFA, namely propionic,  
 280 butyric, and valeric acid could significantly explain any variation across the microbiota composition  
 281 across all samples, and to a minimal extent (Table S17). RDA biplots were constructed to visualise the  
 282 relationships between SIMPER taxa and these SCFAs within both pwCF and healthy controls (Figure

283 S4). Results were mixed, with high variability across particular genera, including *Bacteroides*, *Blautia*,  
 284 *Ruminococcus*, whilst others such as *Faecalibacterium* and *Eubacterium* behaved similarly and were  
 285 more closely clustered. Other taxa were strongly dissociated with the SCFAs from the RDA biplot model,  
 286 including *Blautia* spp. (OTU 1) and *Fusicatenibacter saccharivorans*.



287

288 **Figure 3.** Redundancy analysis species biplots for the whole microbiota. The 24 taxa contributing most to the  
 289 dissimilarity (cumulatively > 50%) between healthy control and pwCF samples following extended ETI therapy from  
 290 the SIMPER analysis (Table 2) are shown independently of the total number of ASVs identified (531). Orange  
 291 points represent taxa that were identified as core for the pwCF group following extended ETI therapy, grey points  
 292 are satellite, and the white (black stroke) points represent taxa that were absent. Biplot lines depict clinical variables  
 293 that significantly account for total variation in taxa relative abundance within whole microbiota analysis at the  $p \leq$   
 294 0.05 level (Table 3). Species plots depict the strength of explanation provided by the given clinical variables,  
 295 with taxa shown in the same direction of a particular clinical variable considered to have a higher value than those that  
 296 are not. 'Abx' – Antibiotics during sampling period, 'SBWC' – Small bowel water content corrected for body surface  
 297 area. The percentage of microbiota variation explained by each axis is given in parentheses.

298

299 Finally, when comparing symptoms and gut function across pwCF and healthy controls, it was evident  
300 that ETI therapy did not significantly improve PAC-SYM scores irrespective of treatment length ( $P >$   
301  $0.05$  in all instances) (Table S18). In terms of functionality, no significant differences in oro-caecal transit  
302 time (OCTT) ( $P = 0.842$ ) or SBWC ( $P = 0.064$ ) between pwCF in this cohort undergoing microbiota  
303 analyses and healthy controls occurred, however the latter was markedly increased (Table S19).  
304

#### 305 4. Discussion

306 As the efficacy of CFTR modulators continues to increase in alleviating respiratory complications of CF,  
307 there is need to clarify whether patient improvements further translate at the site of the intestinal tract.  
308 This includes both GI abnormalities and patient symptoms following CFTR modulator treatment,  
309 including the effects upon the gut microbiota, for which data remain scarce and to the best of our  
310 knowledge has not been characterised in pwCF following ETI therapy. Here we examined the impact  
311 of ETI on the gut microbiota and their associated metabolites, utilising 16S rRNA sequencing and  
312 integrated targeted metabolomics to profile and quantify faecal levels of short-chain fatty acids. Overall,  
313 our results indicate that ETI therapy does impact upon microbiota structure in pwCF, but this remains  
314 distinctly different to that of healthy control participants as observed previously [8,32,33].

315 With respect to microbiota diversity, we demonstrate a significant shift in the core taxa of pwCF following  
316 extended ETI therapy, which translated into a positive trajectory of whole microbiota diversity by the  
317 end of the study period. Despite this, diversity was not significantly different following ETI, as shown  
318 previously with less efficacious CFTR modulator treatments encompassing shorter administration  
319 periods [15–17,19]. Interestingly, Kristensen et al. did observe significant increases in faecal microbiota  
320 diversity [18], but only following extended (12 month) Ivacaftor therapy in a group of pwCF harbouring  
321 the S1251N mutation. Unlike others [15–17,19], they also found that microbiota composition changed  
322 significantly over time, with samples obtained following extended Ivacaftor more tightly clustered [18].  
323 In the current study, the core taxa and whole microbiota became more similar in pwCF as ETI  
324 progressed, also increasing in similarity to healthy controls. There remained, however, a significant  
325 difference in microbiota composition to controls as previously observed throughout life in pwCF [7–  
326 9,24].

327 The significant difference in microbiota composition maintained between pwCF and controls following  
328 extended ETI was driven by taxa previously associated with SCFA production in the gut, including  
329 members of the genera *Faecalibacterium*, *Eubacterium*, and *Blautia* [34,35]. Across pwCF specifically,  
330 *Faecalibacterium* remained a satellite taxa constituent and did not substantially contribute to any  
331 changes in the community from baseline, whilst relative abundances of *Eubacterium* were generally  
332 increased, and *Blautia* species fluctuated over the treatment period in pwCF. This raises the possibility  
333 of increased fitness and subsequent proliferation of particular taxa following altered intestinal fluidity

334 subsequent to CFTR modulation, alongside decreased susceptibility to additional CF-associated  
335 perturbations that typically impacts the rarer satellite taxa. When incorporating targeted metabolomics  
336 to understand any functional changes relating to the aforementioned taxa, we identified no key  
337 differences in pwCF following ETI treatment, further extending with healthy controls for acetic, propionic,  
338 isobutyric, butyric and isovaleric acid. These findings are in agreement with Baldwin-Hunter et al., who  
339 recently analysed colonic aspirates from adult pwCF and controls undergoing surveillance colonoscopy  
340 [36]. Collectively, this may support elements of functional redundancy surrounding major SCFA  
341 production in the distal colon in pwCF [37], and is further supported by the low microbial variation  
342 explained here by faecal SCFA levels when both pwCF and control samples were collated. In contrast,  
343 Vernocchi et al. did demonstrate significant reductions in major SCFAs across children with CF as  
344 compared to controls [38], which raises the possibility of age-dependent functional redundancy. Similar  
345 to Baldwin-Hunter et al. again [36], both valeric and hexanoic acid concentration and relative  
346 abundances were significantly larger in healthy control participants compared to pwCF. Furthermore,  
347 valeric acid did significantly explain variation in the microbiota across all samples collated for analysis,  
348 with those associated taxa typically satellite members of the microbiota in pwCF. Any potential  
349 implications of this remain to be clarified in CF as valeric and hexanoic acid have previously been shown  
350 to significantly decrease within intestinal pro-inflammatory environments as compared to healthy  
351 controls [39].

352 Furthering our analyses to reveal any relationships between clinical data, gut function, and microbiota  
353 structure across participants, we observed a strong impact of CF disease, antibiotic exposure, and age  
354 upon microbiota composition similar to our previous work [24]. CF disease was the primary explanator  
355 of the core taxa, which is unsurprising given the strong associations between CFTR genotype alone  
356 and gut microbiota composition [11]. Alongside the whole microbiota, antibiotic usage was a principal  
357 explanator of satellite taxa composition across participants, again underpinning the relevance of this  
358 partitioned community towards wider microbiota organisation and structure. Within the exclusive  
359 analysis of pwCF, antibiotic usage was a prominent explanator of the bacterial community across all  
360 partitions, second only to age within the satellite taxa analysis and explaining more variance than CF  
361 disease severity and treatment length of ETI. Indeed, antibiotics have previously been shown to  
362 significantly impact community composition across pwCF also taking CFTR modulators, to which the  
363 latter had relatively little impact [17]. Given the speculated systemic impact of pulmonary antibiotics in-



364 turn affecting the gut microbiota [8,24,38,40,41], it still remains in question whether this will persist  
365 following sustained CFTR modulator therapy that commences earlier in life across pwCF [42]. In this  
366 cohort, not all participants were undertaking antibiotic therapy, including those on extended ETI. Of the  
367 pwCF that were administered antibiotics however, levels of exposure were at least maintained during  
368 the extended ETI period. Gut function also continues to explain the microbiota variance across pwCF  
369 and controls [24]. SBWC was not significantly altered following ETI treatment and remains elevated  
370 across pwCF [23], significantly explaining the satellite taxa composition across all participants in this  
371 study. The physiological mechanisms behind this increased SBWC are proposed to result from gastro-  
372 ileal abnormalities in CF [43], including delayed ileal-emptying of small bowel content which might have  
373 consequences for downstream taxa in the large intestine.

374 Relating bacterial taxa from our SIMPER analysis with principal drivers of microbiota variation  
375 determined by the RDA approach revealed associations across species both typically identified as  
376 favourable and adverse to the host with CF disease and antibiotic usage. This included *Blautia* spp.  
377 and *Eubacterium hallii* which contain the functional capacity for anti-inflammatory butyrate synthesis  
378 from a range of substrates [44], but also *Enterococcus* spp. and *Ruminococcus gnavus*, which have  
379 both been shown to be increased in the CF gut and associate with intestinal inflammation [9,45,46],  
380 perhaps indicative of acquired resistance to recurrent antibiotic regimens in CF [47]. Within pwCF  
381 specifically, the relationships between disease severity (determined by FEV1%) and intestinal microbial  
382 composition may suggest the need to further understand the putative lung-gut axis in CF [6,48,49]. The  
383 implications of any taxa change upon host immunology at the site of the intestinal tract remains to be  
384 clarified and moving forward will be aided by the thorough integration of faecal and local intestinal  
385 inflammatory data. Across all participants, age and sex were also explanators of the whole microbiota  
386 and core taxa respectively, associating with taxa such as *Escherichia coli* and *Bifidobacterium*  
387 *adolescentis*. This may be explained in part by the ratio of males to females, alongside the wide age  
388 range of our participants, with the relative abundance of the aforementioned impacted by age across  
389 both CF and general life [40,50–52].

390 Alongside the microbiota analyses, it was evident that patient symptoms, as measured by overall PAC-  
391 SYM scores, were not improved upon treatment with ETI. This is consistent with our previous cohort  
392 undertaking Tezacaftor/Ivacaftor therapy [19], yet Mainz et al. have recently described improvements

393 within pwCF GI symptoms upon ETI therapy when utilising the tailored CFAbd questionnaire [53].  
394 Intestinal inflammation is a common occurrence in pwCF [54–56]. Unfortunately, we were unable to  
395 incorporate faecal calprotectin data into this study due to limited measurement across participants.  
396 Previous modulator studies have reported mixed results in the reduction of faecal calprotectin  
397 [16,57,58]. However, with ETI therapy specifically, there is evidence of a reduction following 6 months  
398 of administration [59].

399 Collectively, our microbiota findings indicate a positive impact of ETI therapy upon core taxa and whole  
400 microbiota structure in pwCF. The significant differences that persist between the CF and healthy  
401 control microbiota suggests changes are further required across the CF satellite taxa to bridge this gap,  
402 which make up a significant portion of the relative community abundance [24], and are typically related  
403 to random environmental perturbations or atypical habitats [60,61]. Based on this, the modulation of  
404 CFTR alone may not be sufficient to rescue a microbiota signature observed across controls within  
405 pwCF, whereby the modulation of such alternate clinical factors primarily explaining the satellite taxa  
406 composition may be also required for an enhanced response to CFTR modulator therapy. This  
407 encompasses pulmonary antibiotic usage, which was a key explanator across our multivariate analyses  
408 and of high prevalence across pwCF undertaking extended ETI. Though not investigated in the current  
409 study, additional research into the ability of specific dietary intake and probiotic usage to shape the  
410 microbiota and patient outcomes is desirable [62–64], especially since resilience of the gut microbiota  
411 has been recently suggested following diet and exercise intervention in pwCF [65]. It could be that long-  
412 term substantial changes to such factors are necessary for subsequent beneficial changes to the  
413 intestinal microbiome in an era of modulator therapy.

414 Comprehensively understanding the impact of more efficacious CFTR modulator therapy itself remains  
415 a top research priority in CF, including the identification of novel compounds or biomarkers to enhance  
416 our understanding of disease management [66,67]. The latter is likely to be aided by continued  
417 integration of additional omics techniques to fully elucidate not only the genetic potential, but  
418 measurable functional alterations upon CFTR modulator usage and changes to the CF lifestyle. This  
419 should include the impact of pulmonary antibiotic towards CF intestinal metabolomic and/or  
420 metaproteomic signatures, given their common, persistent use in clinic and at home. This may extend  
421 further to the utilisation of model experimental systems [68], which with tighter experimental control will

422 aid our future understanding of the aforementioned. Aside from the clear caveat of group size in our  
423 pwCF cohort receiving extended ETI therapy, we acknowledge the relatively large sampling gap  
424 between this period and the preceding sampling point of 6 months within this pilot study. Nonetheless,  
425 our extended sampling period highlights the value of further understanding alternate factors to the sole  
426 presence of disease in altering the CF microbiota, patient symptoms and intestinal abnormalities, as  
427 treatment with CFTR modulators alone may not be optimal to achieve this goal in CF.

## 428 **5. Conclusion**

429 In conclusion, we have demonstrated that ETI therapy in pwCF does lead to change in microbiota  
430 characteristics towards that observed in healthy controls following extended administration, albeit with  
431 negligible difference upon SCFA levels and other clinical outcomes. Collectively the composition of the  
432 microbiota and functional metabolites remained significantly different from healthy controls following  
433 extended therapy. We posit that the trajectory of the CF gut microbiota towards that observed in the  
434 healthy controls was predominately impeded by antibiotics administered to combat respiratory infection.  
435 We recommend future work should employ a combination of frequent/prolonged patient cohort studies  
436 and experimental model system approaches to gain a deeper mechanistic understanding of the effects  
437 of both the CFTR modulator therapies and pulmonary antibiotics on the temporal dynamics of gut  
438 microbiota composition functioning. In turn this could then be related to alleviating and improving  
439 abnormalities of the intestinal tract and patient symptoms in CF.

## 440 **Author contributions**

441 CvdG, DR, ARS, GM, and RM conceived the microbiome study. RM, and LH performed microbiota  
442 sample processing and analysis. RM and CDS carried out the metabolomic analysis. RM, DR, and  
443 CvdG performed the data and statistical analysis. AY, ND, CH, CN, GM, and AS were responsible for  
444 sample collection, clinical data collection, care records, and documentation. RM, AY, and CvdG  
445 verified the underlying data. RM, DR, and CvdG were responsible for the creation of the original draft  
446 of the manuscript. RM, GM, DR, ARS, and CvdG contributed to the development of the final  
447 manuscript. CvdG is the guarantor of this work. All authors read and approved the final manuscript.

448

449

450 **Funding**

451 This work was funded by CF Trust grant (VIA 77) awarded to CvdG and DWR. The wider ‘Gut Imaging  
452 for Function & Transit in Cystic Fibrosis Study 3’ (GIFT-CF3) was supported with funding from a Cystic  
453 Fibrosis Trust grant (VIA 061), a Cystic Fibrosis Foundation award (Clinical Pilot and Feasibility Award  
454 SMYTH18A0-I), and a Vertex Pharmaceuticals Investigator-Initiated Study award (IIS-2018-106697).

455 **Declaration of Competing Interest**

456 RM, CDS, ND, and CH have nothing to disclose. DR and CvdG report grant funding from Vertex  
457 Pharmaceuticals outside of the submitted work. AY, CN, GM, and ARS report grants and speaker  
458 honorarium from Vertex Pharmaceuticals outside the submitted work.

459 **Acknowledgements**

460 We would like to thank Neele Dellschaft, Caroline Hoad, Luca Marciani, and Penny Gowland of the  
461 Sir Peter Mansfield Imaging Centre, University of Nottingham, who acquired the original MRI data for  
462 healthy control participants [23].

463

## 464 References

- 465 [1] S. Smith, N. Rowbotham, G. Davies, K. Gathercole, S.J. Collins, Z. Elliott, S. Herbert, L. Allen,  
466 C. Ng, A. Smyth, How can we Relieve Gastrointestinal Symptoms in people with Cystic  
467 Fibrosis? An International Qualitative Survey, *BMJ Open Respir. Res.* 7 (2020) e000614.  
468 <https://doi.org/10.1136/bmjresp-2020-000614>.
- 469 [2] M. Lopes-Pacheco, CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of  
470 Precision Medicine, *Front. Pharmacol.* 10 (2020) 1662.  
471 <https://doi.org/10.3389/fphar.2019.01662>.
- 472 [3] Cystic Fibrosis Trust, UK Cystic Fibrosis Trust, UK Cystic Fibrosis Registry. 2022 Annual Data  
473 Report, London, 2023.
- 474 [4] Cystic Fibrosis Refresh Top 10 priorities (priority setting in association with the JLA), (2022).  
475 [https://www.jla.nihr.ac.uk/priority-setting-partnerships/cystic-fibrosis-refresh/top-10-](https://www.jla.nihr.ac.uk/priority-setting-partnerships/cystic-fibrosis-refresh/top-10-priorities.htm)  
476 [priorities.htm](https://www.jla.nihr.ac.uk/priority-setting-partnerships/cystic-fibrosis-refresh/top-10-priorities.htm).
- 477 [5] N.J. Rowbotham, S. Smith, Z.C. Elliott, B. Cupid, L.J. Allen, K. Cowan, L. Allen, A.R. Smyth, A  
478 Refresh of the Top 10 Research Priorities in Cystic Fibrosis, *Thorax.* 78 (2023) 840–843.  
479 <https://doi.org/10.1136/thorax-2023-220100>.
- 480 [6] J.C. Madan, D.C. Koestle, B.A. Stanton, L. Davidson, L.A. Moulton, M.L. Housman, J.H.  
481 Moore, M.F. Guill, H.G. Morrison, M.L. Sogin, T.H. Hampton, M.R. Karagas, P.E. Palumbo,  
482 J.A. Foster, P.L. Hibberd, G.A. O'Toole, Serial Analysis of the Gut and Respiratory  
483 Microbiome, *MBio.* 3 (2012) e00251-12. <https://doi.org/10.1128/mBio.00251-12>. Editor.
- 484 [7] M.J. Coffey, S. Nielsen, B. Wemheuer, N.O. Kaakoush, M. Garg, B. Needham, R. Pickford, A.  
485 Jaffe, T. Thomas, C.Y. Ooi, Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and  
486 Functional Dysbiosis, *Sci. Rep.* 9 (2019) 18593. <https://doi.org/10.1038/s41598-019-55028-7>.
- 487 [8] D.G. Burke, F. Fouhy, M.J. Harrison, M.C. Rea, P.D. Cotter, O.O. Sullivan, C. Stanton, C. Hill,  
488 F. Shanahan, B.J. Plant, R.P. Ross, The Altered Gut Microbiota in Adults with Cystic Fibrosis,  
489 *BMC Microbiol.* 17 (2017) 58. <https://doi.org/10.1186/s12866-017-0968-8>.
- 490 [9] M. Kristensen, S.M.P.J. Prevaes, G. Kalkman, G.A. Tramper-Stranders, R. Hasrat, K.M. de  
491 Winter- de Groot, H.M. Janssens, H.A. Tiddens, M. van Westreenen, E.A.M. Sanders, B.  
492 Arets, B. Keijsers, C.K. van der Ent, D. Bogaert, Development of the Gut Microbiota in Early  
493 Life: The Impact of Cystic Fibrosis and Antibiotic Treatment, *J. Cyst. Fibros.* 19 (2020) 553–  
494 561. <https://doi.org/10.1016/j.jcf.2020.04.007>.
- 495 [10] D. Debray, H. El Mourabit, F. Merabtene, L. Brot, D. Ulveling, Y. Chrétien, D. Rainteau, I.  
496 Moszer, D. Wendum, H. Sokol, C. Housset, Diet-Induced Dysbiosis and Genetic Background  
497 Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to  
498 Promote Cholangiopathy in Mice, *Hepatol. Commun.* 2 (2018) 1533–1549.  
499 <https://doi.org/10.1002/hep4.1266>.
- 500 [11] S.M. Meeker, K.S. Mears, N. Sangwan, M.J. Brittnacher, E.J. Weiss, P.M. Treuting, N. Tolley,  
501 C.E. Pope, K.R. Hager, A.T. Vo, J. Paik, C.W. Frevert, H.S. Hayden, L.R. Hoffman, S.I. Miller,  
502 A.M. Hajjar, CFTR Dysregulation Drives Active Selection of the Gut Microbiome, *PLoS Pathog.*  
503 16 (2020) e1008251. <https://doi.org/10.1371/journal.ppat.1008251>.
- 504 [12] M.B. De Freitas, E.A.M. Moreira, C. Tomio, Y.M.F. Moreno, F.P. Daltoe, E. Barbosa, N.L.  
505 Neto, V. Buccigrossi, A. Guarino, Altered Intestinal Microbiota Composition, Antibiotic Therapy  
506 and Intestinal Inflammation in Children and Adolescents with Cystic Fibrosis, *PLoS One.* 13  
507 (2018) e0198457. <https://doi.org/10.1371/journal.pone.0198457>.
- 508 [13] T. Flass, S. Tong, D.N. Frank, B.D. Wagner, C.E. Robertson, C.V. Kotter, R.J. Sokol, E.  
509 Zemanick, F. Accurso, E.J. Hoffenberg, M.R. Narkewicz, Intestinal Lesions are Associated  
510 with Altered Intestinal Microbiome and are More Frequent in Children and Young Adults with  
511 Cystic Fibrosis and Cirrhosis, *PLoS One.* 10 (2015) e0116967.  
512 <https://doi.org/10.1371/journal.pone.0116967>.

- 513 [14] G. Dayama, S. Priya, D.E. Niccum, A. Khoruts, R. Blekhman, Interactions Between the Gut  
514 Microbiome and Host Gene Regulation in Cystic Fibrosis, *Genome Med.* 12 (2020) 12.  
515 <https://doi.org/10.1186/s13073-020-0710-2>.
- 516 [15] C.Y. Ooi, S.A. Syed, L. Rossi, M. Garg, B. Needham, J. Avolio, K. Young, M.G. Surette, T.  
517 Gonska, Impact of CFTR Modulation with Ivacaftor on Gut Microbiota and Intestinal  
518 Inflammation, *Sci. Rep.* 8 (2018). <https://doi.org/10.1038/s41598-018-36364-6>.
- 519 [16] N.J. Ronan, G.G. Einarsson, J. Deane, F. Fouhy, M. Rea, C. Hill, F. Shanahan, J.S. Elborn,  
520 R.P. Ross, M. McCarthy, D.M. Murphy, J.A. Eustace, T. MM, C. Stanton, B.J. Plant,  
521 Modulation, Microbiota and Inflammation in the adult CF Gut: A Prospective Study, *J. Cyst.*  
522 *Fibros.* 21 (2022) 837–843. <https://doi.org/10.1016/j.jcf.2022.06.002>.
- 523 [17] C.E. Pope, A.T. Vo, H.S. Hayden, E.J. Weiss, S. Durfey, S. McNamara, A. Ratjen, B. Grogan,  
524 S. Carter, L. Nay, M.R. Parsek, P.K. Singh, E.F. McKone, M.L. Aitken, M.R. Rosenfeld, L.R.  
525 Hoffman, Changes in Fecal Microbiota with CFTR Modulator Therapy: A Pilot Study, *J. Cyst.*  
526 *Fibros.* 20 (2021) 742–746. <https://doi.org/10.1016/j.jcf.2020.12.002>.
- 527 [18] M.I. Kristensen, K.M. de Winter-De Groot, G. Berkers, M.L.J.N. Chu, K. Arp, S. Ghijsen,  
528 H.G.M. Heijerman, H.G.M. Arets, C.J. Majoor, H.M. Janssens, R. van der Meer, D. Bogaert,  
529 C.K. van der Ent, Individual and Group Response of Treatment with Ivacaftor on Airway and  
530 Gut Microbiota in People with CF and a s1251n Mutation, *J. Pers. Med.* 11 (2021) 350.  
531 <https://doi.org/10.3390/jpm11050350>.
- 532 [19] R. Marsh, C. Dos Santos, L. Hanson, C. Ng, G. Major, A.R. Smyth, D. Rivett, C. van der Gast,  
533 Tezacaftor/Ivacaftor Therapy has Negligible Effects on the Cystic Fibrosis Gut Microbiome.,  
534 *Microbiol. Spectr.* 11 (2023) e0117523. <https://doi.org/10.1128/spectrum.01175-23>.
- 535 [20] C. Tetard, M. Mittaine, S. Bui, F. Beaufils, P. Maumus, M. Fayon, P.-R. Burgel, T. Lamireau, L.  
536 Delhaes, E. Mas, R. Enaud, Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in  
537 Adolescents With Cystic Fibrosis, *J. Pediatr. Gastroenterol. Nutr.* 71 (2020) 778–781.
- 538 [21] V.A. Stallings, N. Sainath, M. Oberle, C. Bertolaso, J.I. Schall, Energy Balance and  
539 Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations, *J.*  
540 *Pediatr.* 201 (2018) 229-237.e4. <https://doi.org/10.1016/j.jpeds.2018.05.018>.
- 541 [22] S.N. Dawood, A.M. Rabih, A. Niaj, A. Raman, M. Uprety, M.J. Calero, M.R.B. Villanueva, N.  
542 Joshaghani, N. Villa, O. Badla, R. Goit, S.E. Saddik, L. Mohammed, Newly Discovered  
543 Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review., *Cureus.* 14  
544 (2022) e29359. <https://doi.org/10.7759/cureus.29359>.
- 545 [23] C. Ng, N.S. Dellschaft, C.L. Hoad, L. Marciani, L. Ban, A.P. Prayle, H.L. Barr, A. Jaudszus,  
546 J.G. Mainz, R.C. Spiller, P. Gowland, G. Major, A.R. Smyth, Postprandial Changes in  
547 Gastrointestinal Function and Transit in Cystic Fibrosis Assessed by Magnetic Resonance  
548 Imaging, *J. Cyst. Fibros.* 20 (2021) 591–597. <https://doi.org/10.1016/j.jcf.2020.06.004>.
- 549 [24] R. Marsh, H. Gavillet, L. Hanson, C. Ng, M. Mitchell-Whyte, G. Major, A.R. Smyth, D. Rivett, C.  
550 van der Gast, Intestinal Function and Transit Associate with Gut Microbiota Dysbiosis in Cystic  
551 Fibrosis., *J. Cyst. Fibros.* 21 (2022) 506–513.  
552 <https://doi.org/https://doi.org/10.1016/j.jcf.2021.11.014>.
- 553 [25] L. Frank, L. Kleinman, C. Farup, L. Taylor, P.J. Miner, Psychometric Validation of a  
554 Constipation Symptom Assessment Questionnaire., *Scand. J. Gastroenterol.* 34 (1999) 870–  
555 877. <https://doi.org/10.1080/003655299750025327>.
- 556 [26] M.A. Gorzelak, S.K. Gill, N. Tasnim, Z. Ahmadi-Vand, M. Jay, D.L. Gibson, Methods for  
557 Improving Human Gut Microbiome Data by Reducing Variability through Sample Processing  
558 and Storage of Stool, *PLoS One.* 10 (2015) e0134802.  
559 <https://doi.org/10.1371/journal.pone.0134802>.
- 560 [27] G.B. Rogers, L. Cuthbertson, L.R. Hoffman, P.A.C. Wing, C. Pope, D.A.P. Hooftman, A.K.  
561 Lilley, A. Oliver, M.P. Carroll, K.D. Bruce, C.J. Van Der Gast, Reducing Bias in Bacterial  
562 Community Analysis of Lower Respiratory Infections, *ISME J.* 7 (2013) 697–706.  
563 <https://doi.org/10.1038/ismej.2012.145>.

- 564 [28] B.J. Callahan, P.J. McMurdie, M.J. Rosen, A.W. Han, A.J.A. Johnson, S.P. Holmes, DADA2:  
565 High Resolution Sample Inference from Illumina Amplicon Data, *Nat. Methods*. 13 (2016) 4–5.  
566 <https://doi.org/10.1038/nmeth.3869>.DADA2.
- 567 [29] N.M. Davis, D.M. Proctor, S.P. Holmes, D.A. Relman, B.J. Callahan, Simple Statistical  
568 Identification and Removal of Contaminant Sequences in Marker-Gene and Metagenomics  
569 Data, *Microbiome*. 6 (2018) 226. <https://doi.org/10.1186/s40168-018-0605-2>.
- 570 [30] Ø. Hammer, D. A.T. Harper, P.D. Ryan, PAST: Paleontological Statistics Software Package for  
571 Education and Data Analysis, *Palaeontol. Electron*. 4 (2001) 9.
- 572 [31] C. ter Braak, P. Smilauer, CANOCO Reference Manual and User's Guide: Software for  
573 Ordination., Ithaca: Microcomputer Power, 2012.
- 574 [32] F. Miragoli, S. Federici, S. Ferrari, A. Minuti, A. Rebecchi, E. Bruzzese, V. Buccigrossi, A.  
575 Guarino, M.L. Callegari, Impact of Cystic Fibrosis Disease on Archaea and Bacteria  
576 Composition of Gut Microbiota, *FEMS Microbiol. Ecol*. 93 (2017) fiw230.  
577 <https://doi.org/10.1093/femsec/fiw230>.
- 578 [33] O. Manor, R. Levy, C.E. Pope, H.S. Hayden, M.J. Brittnacher, R. Carr, M.C. Radey, K.R.  
579 Hager, S.L. Heltshe, B.W. Ramsey, S.I. Miller, L.R. Hoffman, E. Borenstein, Metagenomic  
580 Evidence for Taxonomic Dysbiosis and Functional Imbalance in the Gastrointestinal Tracts of  
581 Children with Cystic Fibrosis, *Sci. Rep*. 6 (2016) 22493. <https://doi.org/10.1038/srep22493>.
- 582 [34] M. Sakamoto, N. Sakurai, H. Tanno, T. Iino, M. Ohkuma, A. Endo, Genome-Based,  
583 Phenotypic and Chemotaxonomic Classification of Faecalibacterium Strains: Proposal of  
584 Three Novel Species *Faecalibacterium duncaniae* sp. nov., *Faecalibacterium hattorii* sp. nov.  
585 and *Faecalibacterium gallinarum* sp. nov., *Int. J. Syst. Evol. Microbiol*. 72 (2022) 005379.  
586 <https://doi.org/10.1099/ijsem.0.005379>.
- 587 [35] D. Parada Venegas, M.K. De la Fuente, G. Landskron, M.J. González, R. Quera, G. Dijkstra,  
588 H.J.M. Harmsen, K.N. Faber, M.A. Hermoso, Short Chain Fatty Acids (SCFAs)-Mediated Gut  
589 Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases, *Front.*  
590 *Immunol*. 10 (2019) 277. <https://www.frontiersin.org/articles/10.3389/fimmu.2019.00277>.
- 591 [36] B.L. Baldwin-Hunter, F.D. Rozenberg, M.K. Annavajhala, H. Park, E.A. DiMango, C.L. Keating,  
592 A.-C. Uhlemann, J.A. Abrams, The Gut Microbiome, Short Chain Fatty Acids, and Related  
593 Metabolites in Cystic Fibrosis Patients with and without Colonic Adenomas., *J. Cyst. Fibros*. 22  
594 (2023) 738–744. <https://doi.org/10.1016/j.jcf.2023.01.013>.
- 595 [37] Y. Wang, L.E.X. Leong, R.L. Keating, T. Kanno, G.C.J. Abell, F.M. Mobegi, J.M. Choo, S.L.  
596 Wesselingh, A.J. Mason, L.D. Burr, G.B. Rogers, Opportunistic Bacteria Confer the Ability  
597 to Ferment Prebiotic Starch in the Adult Cystic Fibrosis Gut, *Gut Microbes*. 10 (2019) 367–381.  
598 <https://doi.org/10.1080/19490976.2018.1534512>.
- 599 [38] P. Vernocchi, F. Del Chierico, A. Russo, F. Majo, M. Rossitto, M. Valerio, L. Casadei, A. La  
600 Storia, F. De Filippis, C. Rizzo, C. Manetti, P. Paci, D. Ercolini, F. Marini, E.V. Fiscarelli, B.  
601 Dallapiccola, V. Lucidi, A. Miccheli, L. Putignani, Gut microbiota signatures in cystic fibrosis:  
602 Loss of host CFTR function drives the microbiota enterophenotype, *PLoS One*. 13 (2018)  
603 e0208171. <https://doi.org/10.1371/journal.pone.0208171>.
- 604 [39] V. De Preter, K. Machiels, M. Joossens, I. Arijis, C. Matthys, S. Vermeire, P. Rutgeerts, K.  
605 Verbeke, Faecal Metabolite Profiling Identifies Medium-Chain Fatty Acids as Discriminating  
606 Compounds in IBD., *Gut*. 64 (2015) 447–458. <https://doi.org/10.1136/gutjnl-2013-306423>.
- 607 [40] G. Duytschaever, G. Huys, M. Bekaert, L. Boulanger, K. De Boeck, P. Vandamme, Dysbiosis  
608 of Bifidobacteria and Clostridium Cluster XIVa in the Cystic Fibrosis Fecal Microbiota, *J. Cyst.*  
609 *Fibros*. 12 (2013) 206–215. <https://doi.org/10.1016/j.jcf.2012.10.003>.
- 610 [41] R. Enaud, K.B. Hooks, A. Barre, T. Barnetche, C. Hubert, M. Massot, T. Bazin, H. Clouzeau,  
611 S. Bui, M. Fayon, P. Berger, P. Lehours, C. Bébéar, M. Nikolski, T. Lamireau, L. Delhaes, T.  
612 Schaevebeke, Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with  
613 Crohn's-Like Microbiota Disturbances, *J. Clin. Med*. 8 (2019) 645.  
614 <https://doi.org/10.3390/jcm8050645>.

- 615 [42] R.H. Keogh, R. Cosgriff, E.R. Andrinopoulou, K.G. Brownlee, S.B. Carr, K. Diaz-Ordaz, E.  
616 Granger, N.P. Jewell, A. Lewin, C. Leyrat, D.K. Schlüter, M. van Smeden, R.D. Szczesniak,  
617 G.J. Connett, Projecting the Impact of Triple CFTR Modulator Therapy on Intravenous  
618 Antibiotic Requirements in Cystic Fibrosis using Patient Registry Data Combined with  
619 Treatment Effects from Randomised Trials, *Thorax*. 77 (2022) 873–881.  
620 <https://doi.org/10.1136/thoraxjnl-2020-216265>.
- 621 [43] N. Dellschaft, C. Hoad, L. Marciani, P. Gowland, R. Spiller, Small Bowel Water Content  
622 Assessed by MRI in Health and Disease: A Collation of Single-Centre Studies., *Aliment.*  
623 *Pharmacol. Ther.* 55 (2022) 327–338. <https://doi.org/10.1111/apt.16673>.
- 624 [44] A. Rivière, M. Selak, D. Lantin, F. Leroy, L. De Vuyst, Bifidobacteria and Butyrate-Producing  
625 Colon Bacteria: Importance and Strategies for their Stimulation in the Human Gut, *Front.*  
626 *Microbiol.* 7 (2016) 979. <https://doi.org/10.3389/fmicb.2016.00979>.
- 627 [45] M.T. Henke, D.J. Kenny, C.D. Cassilly, H. Vlamakis, R.J. Xavier, J. Clardy, *Ruminococcus*  
628 *gnavus*, a Member of the Human Gut Microbiome Associated with Crohn's Disease, Produces  
629 an Inflammatory Polysaccharide, *Proc. Natl. Acad. Sci. U. S. A.* 116 (2019) 12672–12677.  
630 <https://doi.org/10.1073/pnas.1904099116>.
- 631 [46] F. Fouhy, N.J. Ronan, O. O'Sullivan, Y. McCarthy, A.M. Walsh, D.M. Murphy, M. Daly, E.T.  
632 Flanagan, C. Fleming, M. McCarthy, C. Shortt, J.A. Eustace, F. Shanahan, M.C. Rea, R.P.  
633 Ross, C. Stanton, B.J. Plant, A Pilot Study Demonstrating the Altered Gut Microbiota  
634 Functionality in Stable Adults with Cystic Fibrosis, *Sci. Rep.* 7 (2017) 6685.  
635 <https://doi.org/10.1038/s41598-017-06880-y>.
- 636 [47] S.L. Taylor, L.E.X. Leong, S.K. Sims, R.L. Keating, L.E. Papanicolas, A. Richard, F.M. Mobegi,  
637 S. Wesselingh, L.D. Burr, G.B. Rogers, The Cystic Fibrosis Gut as a Potential Source of  
638 Multidrug Resistant Pathogens., *J. Cyst. Fibros.* 20 (2021) 413–420.  
639 <https://doi.org/10.1016/j.jcf.2020.11.009>.
- 640 [48] I. Testa, O. Crescenzi, S. Esposito, Gut Dysbiosis in Children with Cystic Fibrosis:  
641 Development, Features and the Role of Gut-Lung Axis on Disease Progression.,  
642 *Microorganisms.* 11 (2022) 9. <https://doi.org/10.3390/microorganisms11010009>.
- 643 [49] A.G. Hoen, J. Lia, L.A. Moulton, G.A. O'Toole, M.L. Housman, D.C. Koestler, M.F. Guill, J.H.  
644 Moore, P.L. Hibberd, H.G. Morrison, M.L. Sogin, M.R. Karagas, J.C. Madan, Associations  
645 Between Gut Microbial Colonization in Early Life and Respiratory Outcomes in Cystic Fibrosis,  
646 *J. Pediatr.* 167 (2015) 138-147.e1–3. <https://doi.org/10.1016/j.bb.2017.04.008>.
- 647 [50] L.R. Hoffman, C.E. Pope, H.S. Hayden, S. Heltshe, R. Levy, S. McNamara, M.A. Jacobs, L.  
648 Rohmer, M. Radey, B.W. Ramsey, M.J. Brittnacher, E. Borenstein, S.I. Miller, *Escherichia coli*  
649 Dysbiosis Correlates with Gastrointestinal Dysfunction in Children with Cystic Fibrosis, *Clin.*  
650 *Infect. Dis.* 58 (2014) 396–399. <https://doi.org/10.1093/cid/cit715>.
- 651 [51] S. Matamouros, H.S. Hayden, K.R. Hager, M.J. Brittnacher, K. Lachance, E.J. Weiss, C.E.  
652 Pope, A.F. Imhaus, C.P. McNally, E. Borenstein, L.R. Hoffman, S.I. Miller, Adaptation of  
653 Commensal Proliferating *Escherichia coli* to the Intestinal Tract of Young Children with Cystic  
654 Fibrosis, *Proc. Natl. Acad. Sci. U. S. A.* 115 (2018) 1605–1610.  
655 <https://doi.org/10.1073/pnas.1714373115>.
- 656 [52] S. Arbolea, C. Watkins, C. Stanton, R.P. Ross, Gut Bifidobacteria Populations in Human  
657 Health and Aging., *Front. Microbiol.* 7 (2016) 1204. <https://doi.org/10.3389/fmicb.2016.01204>.
- 658 [53] J.G. Mainz, C. Zagoya, L. Polte, L. Naehrlich, L. Sasse, O. Eickmeier, C. Smaczny, A.  
659 Barucha, L. Bechinger, F. Duckstein, L. Kurzidim, P. Eschenhagen, L. Caley, D. Peckham, C.  
660 Schwarz, Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic  
661 Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score, *Front. Pharmacol.* 14  
662 (2022) 1207356. <https://doi.org/10.3389/fphar.2022.877118>.
- 663 [54] A. Munck, Cystic Fibrosis: Evidence for Gut Inflammation., *Int. J. Biochem. Cell Biol.* 52 (2014)  
664 180–183. <https://doi.org/10.1016/j.biocel.2014.02.005>.
- 665 [55] F. Beaufils, E. Mas, M. Mittaine, M. Addra, M. Fayon, L. Delhaes, H. Clouzeau, F. Galode, T.



- 666 Lamireau, Increased Fecal Calprotectin Is Associated with Worse Gastrointestinal Symptoms  
667 and Quality of Life Scores in Children with Cystic Fibrosis, *J. Clin. Med.* 9 (2020) 4080.
- 668 [56] J. Dorsey, T. Gonska, Bacterial Overgrowth, Dysbiosis, Inflammation, and Dysmotility in the  
669 Cystic Fibrosis Intestine, *J. Cyst. Fibros.* 16 (2017) S14–S23.  
670 <https://doi.org/10.1016/j.jcf.2017.07.014>.
- 671 [57] V.A. Stallings, N. Sainath, M. Oberle, C. Bertolaso, J.I. Schall, Energy Balance and  
672 Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations, *J.*  
673 *Pediatr.* 201 (2018) 229-237.e4. <https://doi.org/https://doi.org/10.1016/j.jpeds.2018.05.018>.
- 674 [58] C. Tétard, M. Mittaine, S. Bui, M. Beaufils, F., Maumus, P. Fayon, P.R. Burgel, T. Lamireau, L.  
675 Delhaes, E. Mas, R. Enaud, Reduced Intestinal Inflammation with Lumacaftor/Ivacaftor in  
676 Adolescents with Cystic Fibrosis, *J. Pediatr. Gastroenterol. Nutr.* 71 (2020) 778–781.
- 677 [59] S.J. Schwarzenberg, P.T. Vu, M. Skalland, L.R. Hoffman, C. Pope, D. Gelfond, M.R.  
678 Narkewicz, D.P. Nichols, S.L. Heltshe, S.H. Donaldson, C.A. Frederick, A. Kelly, J.E. Pittman,  
679 F. Ratjen, M. Rosenfeld, S.D. Sagel, G.M. Solomon, M.S. Stalvey, J.P. Clancy, S.M. Rowe,  
680 S.D. Freedman, Elexacaftor/Tezacaftor/Ivacaftor and Gastrointestinal Outcomes in Cystic  
681 Fibrosis: Report of Promise-GI., *J. Cyst. Fibros.* 22 (2022) 282–289.  
682 <https://doi.org/10.1016/j.jcf.2022.10.003>.
- 683 [60] C.J. van der Gast, A.W. Walker, F.A. Stressmann, G.B. Rogers, P. Scott, T.W. Daniels, M.P.  
684 Carroll, J. Parkhill, K.D. Bruce, Partitioning core and satellite taxa from within cystic fibrosis  
685 lung bacterial communities., *ISME J.* 5 (2011) 780–791.  
686 <https://doi.org/10.1038/ismej.2010.175>.
- 687 [61] A.E. Magurran, Species Abundance Distributions Over Time, *Ecol. Lett.* 10 (2007) 347–354.  
688 <https://doi.org/https://doi.org/10.1111/j.1461-0248.2007.01024.x>.
- 689 [62] L.R. Caley, H. White, M.C. de Goffau, R.A. Floto, J. Parkhill, B. Marsland, D.G. Peckham,  
690 Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review., *Dig. Dis. Sci.* 68 (2023) 1797–  
691 1814. <https://doi.org/10.1007/s10620-022-07812-1>.
- 692 [63] S. Esposito, I. Testa, E. Mariotti Zani, D. Cunico, L. Torelli, R. Grandinetti, V. Fainardi, G. Pisi,  
693 N. Principi, Probiotics Administration in Cystic Fibrosis: What Is the Evidence?, *Nutrients.* 14  
694 (2022) 3160. <https://doi.org/10.3390/nu14153160>.
- 695 [64] I. McKay, J. van Dorst, T. Katz, M. Doumit, B. Prentice, L. Owens, Y. Belessis, S. Chuang, A.  
696 Jaffe, T. Thomas, M. Coffey, C.Y. Ooi, Diet and the gut-lung axis in cystic fibrosis - direct &  
697 indirect links., *Gut Microbes.* 15 (2023) 2156254.  
698 <https://doi.org/10.1080/19490976.2022.2156254>.
- 699 [65] R.L. Knoll, V.H. Jarquín-Díaz, J. Klopp, A. Kemper, K. Hilbert, B. Hillen, D. Pfirrmann, P.  
700 Simon, V. Böhner, O. Nitsche, S. Gehring, L. Markó, S.K. Forslund, K. Poplawska, Resilience  
701 and Stability of the CF- Intestinal and Respiratory Microbiome during Nutritional and Exercise  
702 Intervention, *BMC Microbiol.* 23 (2023) 44. <https://doi.org/10.1186/s12866-023-02788-y>.
- 703 [66] J.L. Taylor-Cousar, P.D. Robinson, M. Shteinberg, D.G. Downey, CFTR modulator therapy:  
704 transforming the landscape of clinical care in cystic fibrosis., *Lancet.* 402 (2023) 1171–1184.  
705 [https://doi.org/10.1016/S0140-6736\(23\)01609-4](https://doi.org/10.1016/S0140-6736(23)01609-4).
- 706 [67] K.B. Hisert, S.E. Birket, J.P. Clancy, D.G. Downey, J.F. Engelhardt, I. Fajac, R.D. Gray, M.E.  
707 Lachowicz-Scroggins, N. Mayer-Hamblett, P. Thibodeau, K.L. Tuggle, C.E. Wainwright, K. De  
708 Boeck, Understanding and addressing the needs of people with cystic fibrosis in the era of  
709 CFTR modulator therapy, *Lancet Respir. Med.* 11 (2023) 916–931.  
710 [https://doi.org/https://doi.org/10.1016/S2213-2600\(23\)00324-7](https://doi.org/https://doi.org/10.1016/S2213-2600(23)00324-7).
- 711 [68] G.A. O'Toole, A. Crabbé, R. Kümmerli, J.J. LiPuma, J.M. Bomberger, J.C. Davies, D. Limoli,  
712 V. V Phelan, J.B. Bliska, W.H. DePas, L.E. Dietrich, T.H. Hampton, R. Hunter, C.M.  
713 Khursigara, A. Price-Whelan, A. Ashare, R.A. Cramer, J.B. Goldberg, F. Harrison, D.A. Hogan,  
714 M.A. Henson, D.R. Madden, J.R. Mayers, C. Nadell, D. Newman, A. Prince, D.W. Rivett, J.D.  
715 Schwartzman, D. Schultz, D.C. Sheppard, A.R. Smyth, M.A. Spero, B.A. Stanton, P.E. Turner,  
716 C. van der Gast, F.J. Whelan, R. Whitaker, K. Whiteson, Model Systems to Study the Chronic,

717 Polymicrobial Infections in Cystic Fibrosis: Current Approaches and Exploring Future  
718 Directions, MBio. 12 (2021) e0176321. <https://doi.org/10.1128/mbio.01763-21>.  
719